JP2015096532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015096532A5 JP2015096532A5 JP2014255148A JP2014255148A JP2015096532A5 JP 2015096532 A5 JP2015096532 A5 JP 2015096532A5 JP 2014255148 A JP2014255148 A JP 2014255148A JP 2014255148 A JP2014255148 A JP 2014255148A JP 2015096532 A5 JP2015096532 A5 JP 2015096532A5
- Authority
- JP
- Japan
- Prior art keywords
- rasagiline
- parkinson
- pharmaceutically acceptable
- use according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 210
- 229960000245 rasagiline Drugs 0.000 claims description 209
- 208000018737 Parkinson disease Diseases 0.000 claims description 112
- 150000003839 salts Chemical class 0.000 claims description 103
- 208000024891 symptom Diseases 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 27
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical group CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 claims description 14
- 229960001956 rasagiline mesylate Drugs 0.000 claims description 14
- 230000000648 anti-parkinson Effects 0.000 claims description 7
- 239000000939 antiparkinson agent Substances 0.000 claims description 7
- 230000008717 functional decline Effects 0.000 claims description 7
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 4
- -1 Rebodoba Chemical compound 0.000 claims description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003805 amantadine Drugs 0.000 claims description 4
- 229960001081 benzatropine Drugs 0.000 claims description 4
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 4
- 229960002802 bromocriptine Drugs 0.000 claims description 4
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 4
- 229960004596 cabergoline Drugs 0.000 claims description 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 4
- 229960003337 entacapone Drugs 0.000 claims description 4
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 4
- 229960003089 pramipexole Drugs 0.000 claims description 4
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 4
- 229960001879 ropinirole Drugs 0.000 claims description 4
- 229960003179 rotigotine Drugs 0.000 claims description 4
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 4
- 229960003946 selegiline Drugs 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 4
- 229960004603 tolcapone Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 104
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13193608P | 2008-06-13 | 2008-06-13 | |
| US61/131,936 | 2008-06-13 | ||
| US18972408P | 2008-08-22 | 2008-08-22 | |
| US61/189,724 | 2008-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Division JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234976A Division JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015096532A JP2015096532A (ja) | 2015-05-21 |
| JP2015096532A5 true JP2015096532A5 (enExample) | 2015-07-02 |
Family
ID=41415378
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Pending JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
| JP2014255148A Pending JP2015096532A (ja) | 2008-06-13 | 2014-12-17 | パーキンソン病緩和のためのラサギリン |
| JP2016234976A Withdrawn JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Pending JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234976A Withdrawn JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090312436A1 (enExample) |
| EP (2) | EP2666356A1 (enExample) |
| JP (3) | JP2011522892A (enExample) |
| CN (2) | CN103893160A (enExample) |
| AU (2) | AU2009258151A1 (enExample) |
| BR (1) | BRPI0909894A2 (enExample) |
| CA (1) | CA2727022A1 (enExample) |
| EA (1) | EA201170018A1 (enExample) |
| IL (1) | IL209131A0 (enExample) |
| MX (1) | MX2010013766A (enExample) |
| NZ (1) | NZ589445A (enExample) |
| WO (1) | WO2009151625A1 (enExample) |
| ZA (1) | ZA201008484B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| EP2194780A4 (en) * | 2007-09-05 | 2010-10-27 | Teva Pharma | METHOD FOR TREATING GLAUCOMA BY RASAGILINE |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| ES2389353T3 (es) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
| WO2009154777A2 (en) | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| US8080584B2 (en) * | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| RS53504B1 (sr) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | Soli razagilina i njihovi farmaceutski preparati |
| EP2939669A1 (en) * | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
| AU2011282716A1 (en) * | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| EA201390613A1 (ru) * | 2010-10-26 | 2013-11-29 | Тева Фармасьютикал Индастриз Лтд. | Обогащенный дейтерием расагилин |
| CA2732440C (en) * | 2011-02-23 | 2017-10-31 | Universite Laval | Cystamine analogues for the treatment of parkinson`s disease |
| US20130089611A1 (en) * | 2011-10-10 | 2013-04-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline citramide |
| KR20140090996A (ko) | 2011-10-10 | 2014-07-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | R(+)-n-폼일-프로파길-아미노인단 |
| AU2012323351A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-methyl-propargyl-aminoindan |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
| JP2017517481A (ja) * | 2014-04-01 | 2017-06-29 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンに対する応答を予測するために有用な一塩基多型の決定 |
| EP3432931A1 (en) * | 2016-03-26 | 2019-01-30 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositons for n-propargylamine derivative |
| WO2018187467A1 (en) * | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| JP7473565B2 (ja) * | 2019-01-28 | 2024-04-23 | ミトコンドリア エモーション， インク． | マイトフュージン活性化物質及びその使用方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69732984T2 (de) * | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| WO2003007803A2 (en) * | 2001-07-20 | 2003-01-30 | Mount Sinai School Of Medicine Of New York University | Methods for diagnosing and treating alzheimer's disease and parkinson's disease |
| CN1589153A (zh) * | 2001-12-28 | 2005-03-02 | 武田药品工业株式会社 | 排尿紊乱的预防或治疗 |
| EP2526944B1 (en) * | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| KR20140103356A (ko) * | 2005-02-23 | 2014-08-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
| EP1954667B1 (en) * | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EA016820B1 (ru) * | 2006-12-14 | 2012-07-30 | Тева Фармасьютикал Индастриз, Лтд. | Кристаллическое твердое основание разагилина |
| WO2008076315A1 (en) * | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032202A1 (en) * | 2007-08-29 | 2009-03-12 | Nuon Therapeutics, Inc. | Treatment of brain disorders |
| EP2194780A4 (en) * | 2007-09-05 | 2010-10-27 | Teva Pharma | METHOD FOR TREATING GLAUCOMA BY RASAGILINE |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| ES2389353T3 (es) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| WO2009154777A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US8080584B2 (en) * | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| US20110130466A1 (en) * | 2009-10-09 | 2011-06-02 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2939669A1 (en) * | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
-
2009
- 2009-06-12 JP JP2011513503A patent/JP2011522892A/ja active Pending
- 2009-06-12 WO PCT/US2009/003528 patent/WO2009151625A1/en not_active Ceased
- 2009-06-12 US US12/456,166 patent/US20090312436A1/en not_active Abandoned
- 2009-06-12 CA CA2727022A patent/CA2727022A1/en not_active Abandoned
- 2009-06-12 EA EA201170018A patent/EA201170018A1/ru unknown
- 2009-06-12 CN CN201310714021.5A patent/CN103893160A/zh active Pending
- 2009-06-12 EP EP20130176166 patent/EP2666356A1/en not_active Withdrawn
- 2009-06-12 NZ NZ589445A patent/NZ589445A/xx unknown
- 2009-06-12 BR BRPI0909894-1A patent/BRPI0909894A2/pt not_active IP Right Cessation
- 2009-06-12 EP EP09762921A patent/EP2296462A4/en not_active Withdrawn
- 2009-06-12 CN CN2009801230031A patent/CN102065687A/zh active Pending
- 2009-06-12 AU AU2009258151A patent/AU2009258151A1/en not_active Abandoned
- 2009-06-12 MX MX2010013766A patent/MX2010013766A/es not_active Application Discontinuation
-
2010
- 2010-11-04 IL IL209131A patent/IL209131A0/en unknown
- 2010-11-25 ZA ZA2010/08484A patent/ZA201008484B/en unknown
-
2013
- 2013-11-27 US US14/092,526 patent/US20140243418A1/en not_active Abandoned
-
2014
- 2014-12-17 JP JP2014255148A patent/JP2015096532A/ja active Pending
-
2016
- 2016-11-15 AU AU2016259315A patent/AU2016259315A1/en not_active Abandoned
- 2016-12-02 JP JP2016234976A patent/JP2017081938A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015096532A5 (enExample) | ||
| Oertel et al. | Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe | |
| Maggini et al. | A combination of high-dose vitamin C plus zinc for the common cold | |
| JP2019511488A5 (enExample) | ||
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| EP3684411A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| JP2015505564A5 (enExample) | ||
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| JP2017510607A5 (enExample) | ||
| WO2016083875A1 (en) | Medicaments for slowing parkinson's disease | |
| JP2016510343A5 (enExample) | ||
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| Roth et al. | The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study | |
| JP2016505050A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| JP2018505901A5 (enExample) | ||
| JP2018505901A (ja) | 統合失調症の治療のためのイロペリドン | |
| RU2325146C1 (ru) | Способ реабилитации больных рассеянным склерозом с нарушениями двигательных функций | |
| JP2018500375A5 (enExample) | ||
| Godse et al. | “Busting” urticaria with a “burst” of steroids | |
| JP2017511307A5 (enExample) | ||
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції |